Bioiberica has announced its participation at CPHI 2023, where it is set to present research for digestive and skin health branded ingredients
Bioiberica is set to participate in CPHI 2023, where it will showcase its investment in scientific research, sustainable development and strategic partnerships for a more resilient future.
Alongside its market-leading API portfolio, the company will present the latest research for its mobility, digestive and skin health branded ingredients. Attendees will also have the opportunity to explore Bioiberica’s newfound focus on advanced wound care – a captivating area of research in the medical nutrition arena, as well as find out more about the company's sustainability goals following the publication of its 2023 climate strategy report.
Bioiberica will exhibit its essential APIs – chondroitin sulfate and glucosamine for the symptomatic treatment of osteoarthritis, thyroid for endocrinology and its flagship ingredient, Heparin.
CPHI offers us a platform to highlight the substantial strides we’ve made to strengthen these foundations and showcase how we’re supporting our customers
- Luis Solera, CEO at Bioiberica
For the first time, it will spotlight its expertise in wound care too; sharing the scientific data set to unlock a new world of co-innovation possibilities. On stand, the company will also present the latest research supporting the efficacy of its branded ingredients – Collavant n2 (native (undenatured) type II collagen), Mobilee (hyaluronic acid matrix ingredient) for joint health and mobility, Dermial (hyaluronic acid matrix ingredient) for skin health and DAOgest (diamine oxidase enzyme) for histamine intolerance.
With sustainability top of the agenda for the pharmaceutical industry, Bioiberica will illuminate the transformative potential of its latest sustainability initiatives and how they’re helping to enhance its customers’ green credentials in the face of mounting pressures. Attendees can connect with Bioiberica’s experts on booth 7P20 to learn more about its circular bioeconomy model, targets to obtain 100% renewable electricity by 2024 and 30% less GHG emissions by 2030, and ambitious plans to achieve climate neutrality by 2050.
“CPHI is always a fantastic opportunity to connect with customers – new and old – but the excitement has been taken up a notch this year as we welcome key stakeholders from across the global pharmaceutical landscape to our hometown, Barcelona,” said Luis Solera, CEO at Bioiberica.
“Progression in the healthcare space hinges on three key pillars: science, sustainability and strategic partnership. CPHI offers us a platform to highlight the substantial strides we’ve made to strengthen these foundations and showcase how we’re supporting our customers in addressing some of the most pressing challenges facing the pharmaceutical industry. Visitors are warmly invited to our booth where we look forward to fostering innovative ideas together," continued Solera.